BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22270451)

  • 21. [Correlation between matrix metalloproteinases-2 and tissue inhibitor of metalloproteinase-2 expression, metastatic potential and tumor angiogenesis in synovial sarcoma and its prognostic significance].
    Sun BC; Sun Y; Zhao XL; Wang J; Wang X; Liu YX
    Zhonghua Bing Li Xue Za Zhi; 2006 Mar; 35(3):155-8. PubMed ID: 16630504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer.
    Tunuguntla R; Ripley D; Sang QX; Chegini N
    Gynecol Oncol; 2003 Jun; 89(3):453-9. PubMed ID: 12798711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significance of matrix metalloproteinase-7 [correction of matrix metalloproteinase-2], -11 and tissue inhibitor of metalloproteinase-1 expression in normal, hyperplastic and neoplastic endometrium.
    Obokata A; Watanabe J; Nishimura Y; Arai T; Kawaguchi M; Kuramoto H
    Anticancer Res; 2007; 27(1A):95-105. PubMed ID: 17352221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer.
    Nakopoulou L; Katsarou S; Giannopoulou I; Alexandrou P; Tsirmpa I; Panayotopoulou E; Mavrommatis J; Keramopoulos A
    Mod Pathol; 2002 Jan; 15(1):26-34. PubMed ID: 11796838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
    Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
    Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study.
    Graesslin O; Cortez A; Fauvet R; Lorenzato M; Birembaut P; Daraï E
    Ann Oncol; 2006 Apr; 17(4):637-45. PubMed ID: 16407419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein.
    Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
    Clin Cancer Res; 2005 May; 11(9):3257-64. PubMed ID: 15867221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Activity of matrix metalloproteinases -2 and -9 (MMP-2 and MMP-9) and content of their tissue inhibitors in endometrial cancer--a preliminary study].
    Bogusiewicz M; Stryjecka-Zimmer M; Rechberger T
    Ginekol Pol; 2007 May; 78(5):366-72. PubMed ID: 17867327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
    Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
    Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclin D1 is significantly associated with stage of tumor and predicts poor survival in endometrial carcinoma patients.
    Khabaz MN; Abdelrahman AS; Butt NS; Al-Maghrabi B; Al-Maghrabi J
    Ann Diagn Pathol; 2017 Oct; 30():47-51. PubMed ID: 28965628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
    Wei QY; Wu YQ; Fan SQ
    Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.
    Steffensen KD; Waldstrøm M; Christensen RK; Bartels A; Brünner N; Jakobsen A
    BMC Cancer; 2010 May; 10():185. PubMed ID: 20459644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CyclinD1, a prominent prognostic marker for endometrial diseases.
    Liang S; Mu K; Wang Y; Zhou Z; Zhang J; Sheng Y; Zhang T
    Diagn Pathol; 2013 Aug; 8():138. PubMed ID: 23947899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of TIMP-1 immune expression and tumor recurrence in localized prostate cancer.
    Reis ST; Viana NI; Iscaife A; Pontes-Junior J; Dip N; Antunes AA; Guimarães VR; Santana I; Nahas WC; Srougi M; Leite KR
    Int Braz J Urol; 2015; 41(6):1088-95. PubMed ID: 26742965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data.
    Alkushi A; Clarke BA; Akbari M; Makretsov N; Lim P; Miller D; Magliocco A; Coldman A; van de Rijn M; Huntsman D; Parker R; Gilks CB
    Mod Pathol; 2007 Nov; 20(11):1156-65. PubMed ID: 17717550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of MMSET in endometrial cancer: a clinicopathologic study.
    Xiao M; Yang S; Chen J; Ning X; Guo L; Huang K; Sui L
    J Surg Oncol; 2013 Mar; 107(4):428-32. PubMed ID: 22886632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of tissue inhibitors of metalloproteinases (TIMPs) in colorectal carcinoma.
    Joo YE; Seo KS; Kim J; Kim HS; Rew JS; Park CS; Kim SJ
    J Korean Med Sci; 1999 Aug; 14(4):417-23. PubMed ID: 10485622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Localization of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic, and neoplastic endometrium. Enhanced expression by endometrial adenocarcinomas is associated with low differentiation.
    Määttä M; Soini Y; Liakka A; Autio-Harmainen H
    Am J Clin Pathol; 2000 Sep; 114(3):402-11. PubMed ID: 10989641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.